ArticleMedicine2026
Prognostic value of cardiac troponin I in hospitalized patients with community-acquired pneumonia: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac involvement is increasingly recognized in patients with community-acquired pneumonia (CAP). This study aimed to investigate the association between baseline troponin I levels and clinical outcomes, including overall survival, among hospitalized patients with CAP who underwent clinician-directed cardiac evaluation. In this retrospective cohort study, 491 patients were stratified according to baseline cardiac troponin I level (<19.8 ng/L vs ≥19.8 ng/L). Demographic characteristics, comorbidities, laboratory and echocardiographic findings, and clinical outcomes were compared between groups. Survival was analyzed using Kaplan-Meier methods and Cox proportional hazards regression. The median age was 67 years, and 66% were male. Elevated troponin I was detected in 140 patients (28.5%) who were older and had higher rates of coronary artery disease, congestive heart failure, and chronic renal failure, as well as higher Charlson Comorbidity Index (CCI) and Pneumonia Severity Index scores (all P < .05). These patients also had lower left ventricular ejection fraction, higher rates of intensive care unit admission, and in-hospital mortality. During a median follow-up of 439 days, 167 patients (34%) died. Kaplan-Meier analysis showed significantly reduced overall survival in patients with elevated troponin I levels (log-rank P < .001). In multivariate Cox regression analysis, male gender, elevated troponin I (hazard ratio [HR] = 2.016), higher CCI (HR = 1.275), increased blood urea nitrogen to albumin ratio (HR = 2.876), lower hemoglobin levels (HR = 0.841), and reduced ejection fraction (HR = 0.964) were independently associated with mortality. Elevated baseline troponin I was associated with increased mortality and reduced overall survival in this selected high-risk patient population. However, its discriminative performance for mortality was modest (area under the curve [AUC] = 0.64) and lower than that of CCI (AUC = 0.73). The addition of troponin I to a model including age and CCI resulted in only minimal improvement in discrimination (AUC 0.721 vs 0.724), indicating limited incremental prognostic value beyond established risk indices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.